KR100832321B1 - Healthy food comprising Red ginseng acid polysaccharide for hyperlipidemia improvement - Google Patents

Abstract

The present invention relates to a health functional food containing red ginseng acid polysaccharide (hereinafter referred to as 'RGAP') for improving hyperlipidemia. In detail, the present invention relates to a RGAP-containing health functional food having a function of selectively reducing the concentration of triglycerides for exogenous hyperlipidemia and for reducing the concentration of triglycerides and cholesterol for endogenous hyperlipidemia.

Hyperlipidemia, Red Ginseng Acid Polysaccharide, RGAP, Health Functional Food

Description

Healthy food comprising Red ginseng acid polysaccharide for hyperlipidemia improvement

The present invention relates to a health functional food for improving hyperlipidemia containing red ginseng acid polysaccharide (Red ginseng acid polysaccharide; hereinafter referred to as 'RGAP') having a function of reducing the concentration of triglyceride or cholesterol.

There is an increasing number of obese people due to lack of westernized diet and exercise, which is accompanied by hyperlipidemia. Hyperlipidemia refers to a condition in which fat is high in the blood. This means an increase in plasma cholesterol or triglycerides. Hyperlipidemia is not a symptom by itself, but a problem because it is a risk factor such as atherosclerosis, hypertension, and cardiovascular disease due to the increase of blood cholesterol or triglyceride. In other words, hyperlipidemia can cause life-threatening atherosclerosis and can cause pancreatitis, so management is very important. In particular, diet is the most basic of all hyperlipidemia symptoms, so daily fat intake should be less than 30%, vegetable fat instead of animal fat, butter, cheese, milk, beef, pork, chicken, chocolate, Foods that are high in saturated fats, such as margarine, should be taken less often, such as limited or careful food, which can interfere with your diet. Therefore, it is necessary to develop functional food materials to improve the diet of hyperlipidemic patients or the general public who want to prevent them.

Cholesterol is essential as a component of the plasma membrane of cells, as a source of steroid hormones in the adrenal and gonads, as a source of bile, and as a component of blood lipoproteins. About 80% is synthesized by the liver itself, and the remaining 20% is obtained from food, so endogenous hyperlipidemia is more than a metabolism of cholesterol. Excessive intake of high cholesterol food from food causes exogenous hyperlipidemia.

Triglycerides are produced by the absorption of fat from food into the blood in the intestine and into the blood after excess calories from the liver are converted into fat, so eating a lot of fatty foods is likely to cause endogenous hyperlipidemia.

Therefore, among the various natural food ingredients for hyperlipidemia, it is necessary to develop a substance having a function of reducing the concentration of cholesterol or triglycerides that can cause hyperlipidemia while maintaining the cholesterol necessary for the human body.

On the other hand, ginseng, which is known as a medicine for brazier, maturity, ripening, and nerves, has been shown to prevent the development of arteriosclerosis and damage vascular endothelial cells by expanding peripheral blood vessels and improving blood circulation. It is known to have a protective effect (ND Kim. Vasorelaxant effect of ginseng and role of endothelium. J. Ginseng Res. 16 (1). 78. 1992). In detail, the results of clinical trials in which Korean ginseng was administered to adult men and women prevented arteriosclerosis, such as the increase of HDL-cholesterol, the improvement of the atherosclerotic index, and the decrease of the β-lipoprotein. It was found to be valid for (中 西辛 三. 1980. 臨 床 と 硏 究, 57 (9), 323, M. Yamamoto, T. Uemura, S. Nkama, M. Uemiya and A. Kumagai. 1983. Serum HDL- cholesterol increasing and fatty liver-improving actions of Panax ginseng in high cholesterol diet-fed rats with clinical effect on hyperlipidemia in man.AJ of Chinese Medicine. 4. 96-101).

In particular, saponin component of ginseng promotes enzyme activity related to lipid metabolism of blood cholesterol (CN Joo. 1980. The effect of ginseng saponin on hypercholesterolemia induced by prolonged cholesterol feeding in rabbits.Korean Biochemical.J. 13 (1) ), 51-59), have been shown to promote hypercholesterolemia, an important risk factor for atherosclerosis by promoting cholesterol turnover (M. Yamamoto and T. Uemura. 1984. Long-term ginseng effects on hyperlipidaemia in man with further study of its action on atherogenesis and fatty liver in rats.Proc. 4th Int'l Ginseng Symp. 13-20), Ginsenoside Albitu (ginsenoside Rb ₂ ) in ginseng saponin And excretion and atherosclerosis caused by hypercholesterolemia (T. Yokozawa et. Al. 1985. Studies on the mechanism of the hypoglycemic activity of ginsenoside-Rb ₂ in streptoz otocin-diabetic rats.Chem . Pharm.Bull . 33. 869-872).

Among the components of phosphoric acid, polysaccharides, which are non-saponins, have been reported to have immunomodulatory effect, anticancer effect, antidiabetic effect and anti-ulcer effect.In China, polysaccharide fractions are used clinically to treat cancer and certain effects on gastric and colorectal cancers. It is reported to indicate. 21 non-saponin water-soluble substances have been reported from white ginseng, including glycan (panaxan A-U), a glycan. Among them, 8 kinds of acidic polysaccharides are known as neutral polysaccharides. Generally, acidic polysaccharides are polysaccharides in which galacturonic acid, glucuronic acid, and mannuronic acid are combined with polysaccharides, and have a molecular weight of 15,000 or more. In particular, in the case of acidic polysaccharides, cancer cell secretion toxin (Toxohormone L) antagonism, body fat degradation inhibition and cancer patients weight loss inhibitory effect is known. In addition, it has been reported by the present inventors that the acidic polysaccharide fraction of white ginseng has anti-cancer drug (cyclophosphamide) immunotoxicity inhibitory effect, cancer suppression of cancer cells (sarcoma-180) transplanted mouse and enhancement of phagocytic activity of the intranet system. (Kim, YS et al., Arch. Pharm. Res., 13: 330, 1990). In addition, Jinsan, a protein polysaccharide isolated from white ginseng, contains 40-50% of glucose and galactose, 41-45% of acidic sugar galacturonic acid, 3.7-5.2% of protein, and molecular weight of 50-150 kD. It is known to exhibit an enhancement effect (Korean Patent No. 144130). In addition, zinic acid has been reported to show anti-cancer effects as an immunomodulatory function against benzopyrene (BP) -induced mouse lung tumors and to act as an endogenous cytokine derivative (cytokine inducer), showing an immunologically preventive effect of cancer.

However, as can be seen in the prior art regarding the components of the ginseng, the efficacy associated with hyperlipidemia is not known for polysaccharides, and in particular, such functions are not known for acidic polysaccharides.

Herbal medicines, which are also used as ingredients for health functional foods, vary in form depending on their origin, place of origin, and numerical methods, and have different constituents and pharmacological activities. Among the herbal medicines used for herbal medicines, there are many examples of using herbal medicines after specific processing, in addition to using fresh ingredients or dried ones. Ginseng is also classified into white and red ginseng according to the value of processing aid. White ginseng is processed by drying ginseng as it is, red ginseng is steamed by drying ginseng (containing about 70% water). As red ginseng steams and dries ginseng, starch is gelatinized and the browning reaction is accelerated, and the appearance is pale brown to reddish brown. The active ingredient in the preparation of red ginseng is accompanied by chemical changes, and saponins, known as ginseng's active ingredients, are partially converted into saponins unique to red ginseng by numerical values during red ginseng production. In addition, such chemical changes also occur in polysaccharides, which has been found by the present inventors to produce RGAP having a composition different from the protein polysaccharide of ginseng, and it is also known that such RGAP may be usefully used as an anticancer immunomodulator (Korean patent) 450061).

Therefore, while the present inventors are studying the material of functional foods for hyperlipidemia that can be remarkably improved by diet alone, the concentration of cholesterol in RGAP, which is completely different from ginseng and saponin or polysaccharides, is constant in exogenous hyperlipidemia. On the other hand, the concentration was specifically decreased with respect to the content of triglycerides, and in endogenous hyperlipidemia, the concentrations of cholesterol and triglyceride were also reduced, and RGAP-containing health functional foods for improving hyperlipidemia were completed.

Therefore, the present invention is to provide a health functional food containing the same by developing a natural food material that can significantly improve the symptoms of hyperlipidemia by diet alone.

The present invention provides a health functional food containing red ginseng acid polysaccharide (hereinafter referred to as 'RGAP') for improving hyperlipidemia.

Hereinafter, the present invention will be described in detail.

RGAP of the present invention is isolated from red ginseng, 41.6-60.0 mol% of glucuronic acid, 2.5-7.5 mol% of galacturonic acid, 18.8-33.4 mol% of glucose, arabinose ( arabinose) is an acidic polysaccharide containing 1.1 to 2.1 mol% and having a molecular weight of 12,000 to 450,000.

The RGAP is preferably prepared by the method of Korean Patent No. 4,50061.

Hyperlipidemia refers to a condition in which the amount of fat in the blood is increased because triglyceride (TG) and cholesterol (Cholesterol) are not properly metabolized. The causes of hyperlipidemia are largely divided into external factors such as food, and internal factors such as heredity and abnormalities of lipid metabolism.

About 80% of cholesterol is synthesized by the liver itself, and the remaining 20% is obtained from food. Endogenous hyperlipidemia is often an abnormal metabolism of cholesterol. Excessive intake of high cholesterol food from food causes exogenous hyperlipidemia. Triglycerides are produced by the absorption of fat from food into the blood in the intestine and into the blood after excess calories from the liver are converted into fat, so eating a lot of fatty foods is likely to cause endogenous hyperlipidemia.

Therefore, it is possible to control metabolic abnormalities of triglycerides which are almost entirely dependent on external factors in order to improve hyperlipidemia due to recent westernized diet. In addition, hyperlipidemia caused by metabolic abnormalities of cholesterol generated by more than 80% according to internal factors has been required to develop functional food materials that can be effectively used for hyperlipidemia because both metabolic abnormalities of cholesterol and triglycerides can be smoothed.

The RGAP of the present invention was confirmed to decrease the concentration specifically for the content of triglycerides while maintaining a constant concentration of cholesterol in exogenous hyperlipidemia. In addition, in endogenous hyperlipidemia, by confirming that the concentration of cholesterol and triglycerides are reduced, the RGAP can be effectively used to improve hyperlipidemia.

In addition, the present invention can be prepared by the known method by adding the red ginseng acid polysaccharide to a conventional palate food, and can also be formulated in a general formulation, other components in addition to the above components are those skilled in the art according to the formulation Can be selected and blended suitably.

Hereinafter, the present invention will be described in detail by examples. However, the following examples are only for illustrating the present invention, and the scope of the present invention is not limited by the examples.

Preparation Example 1 Preparation of RGAP

RGAP was prepared according to the method described in Korean Patent No. 450061.

10L of 85% ethanol was added to 1kg of red ginseng, extracted three times at 70 ° C, and centrifuged to recover the residue. The collected residue was air dried and extracted four times with 10 L of water at 80 ° C. to obtain a water-soluble extract. The aqueous extract was dialyzed with distilled water for 4 days in a refrigerating chamber using a dialysis membrane having a molecular weight cut-off value of 12 kD or more to obtain a polymer dialysis solution of 12 kD or more, which was centrifuged at 8,000 rpm for 20 minutes to obtain a supernatant. RGAP was prepared by freezing and drying the precipitate obtained by adding 85% ethanol 5 times the weight of the supernatant to the supernatant and centrifuging (8,000 rpm, 30 minutes) therefrom.

Example 1 Preparation of Tablets Containing RGAP

RGAP 5.0 wt% prepared in Preparation Example 1, 65.0 wt% starch, 17.5 wt% lactose, 5.0 wt% magnesium stearate, 2.5 wt% vitamin C, 5.0 wt% mannitol, containing RGAP in a conventional tablet manufacturing method A tablet was prepared.

Example 2 Preparation of Capsules Containing RGAP

A capsule containing RGAP was prepared by filling a capsule with a conventional method of preparing a capsule at a compounding ratio of 5.0 wt% of RGAP prepared in Preparation Example 1, 90.0 wt% of carboxymethyl cellulose, and 5.0 wt% of magnesium stearate.

Example 3 Preparation of Noodles Containing RGAP

7% by weight of the RGAP powder prepared in Preparation Example 1, 48% by weight of wheat flour, 37% by weight of starch, 8% by weight of black soybean flour, noodle containing RGAP was prepared by a conventional noodle manufacturing method.

Example 4 Preparation of Drink Containing RGAP

RGAP 7.0 wt% prepared in Preparation Example 1, concentrated apple juice 13.0 wt%, vitamin C 2.0 wt%, citric acid 15.0 wt%, trisodium citrate 2.5 wt%, drink flavora, sodium benzoate 2.5 wt% and the balance is purified water Formulated to sterilize for 20 seconds at 90 ℃ or more and then sterilized for 30 minutes at 85 ℃ to prepare a beverage containing RGAP.

Experimental Example 1 Antihyperlipidemic Effect Test on Exogenous Hyperlipidemia-Induced Experimental Animal

end. Experiment method

After fasting the rats (SP.D rat, about 200g) for 24 hours, the RGAP prepared in Preparation Example 1 was orally administered once per dose of 100 mg / kg, 200 mg / kg, 300 mg / kg, and 500 mg / kg for 2 hours. After corn oil (corn oil) was administered orally to the rats (dose 2.0g / kg). After 2 hours, serum was collected from the heart of rats and serum was isolated. The results were shown in Table 1 by measuring the clinical biochemical index related to hyperlipidemia from serum using a biochemical analyzer (Automatic Analyzer, Hitachi 7020, Tokyo, Japan). The normal group is a group that does not cause hyperlipidemia, and the control group is a group that is treated with corn oil in the same manner as the sample group and does not receive any treatment. In the sample administration group, the inhibition rate of the biochemical index compared to the normal group was calculated as `` inhibition rate (%) = 100-(blood concentration at sample administration-blood concentration in normal group) / (control blood concentration-blood concentration in normal group) x 100 ''. It is shown by the method.

I. Experiment result

Test group Single dose (mg / kg)   Total cholesterol (mg / dl) Triglyceride (mg / dl) Corn oil RGAP  Normal - -  105.3 ± 16.6  160.2 ± 58.2  Control 2,000 -   92.1 ± 10.6 313.2 ± 122.6 ^*  RGAP 100 2,000 100  104.0 ± 9.2 271.7 ± 163.0 ^{*, #}  RGAP 200 2,000 200   97.4 ± 17.4 256.3 ± 129.4 ^{*, #}  RGAP 300 2,000 300  104.6 ± 17.5 194.9 ± 59.9 ^{*, #}  RGAP 500 2,000 500   97.1 ± 7.8  165.6 ± 40.1  *: p <0.05 control group vs. sample group, #: normal group vs. sample group

As shown in Table 1, when only corn oil was administered, the content of triglycerides was increased from 160.2 mg / dl of the normal group to 313.2 mg / dl of the control group, leading to an increase in concentration of triglycerides about 2 times. On the other hand, the sample RGAP 100mg / kg group was 271.7 mg / dl, which was 27.2% inhibition compared to the normal control group, and the sample RGAP 200mg / kg group was 256.3 mg / dl, which was 37.2% inhibited, and the sample RGAP 300 mg / kg group was 194.9 mg / dl. 77.3% inhibition, the sample RGAP 500mg / kg administration group was 165.6 mg / dl showed an inhibitory effect of 96.5%, indicating that RGAP has a dose-dependent effect of reducing the blood triglyceride content in the body.

However, no change in concentration was observed in the total cholesterol.

Therefore, the red ginseng acid polysaccharide of the present invention can effectively improve exogenous hyperlipidemia by maintaining a constant concentration of cholesterol with little change in content due to external factors, and selectively reducing the concentration of triglycerides that have a total effect on exogenous activity.

Experimental Example 2 Antihyperlipidemic Effect Experiment Using Endogenous Hyperlipidemic-Induced Animal Model

end. Experiment method

Endogenous hyperlipidemia was induced by administration of Triton (WR-1339), and then the effect was assayed by administering the RGAP sample prepared in Preparation Example 1. The rats (SP.D rat, about 200g) was fasted for 24 hours after oral administration of RGAP samples 100mg / kg, 200mg / kg, 500mg / kg, 1000mg / kg for 1 time / day and 3 days. One hour after the RGAP sample was administered again, Triton WR-1339 was administered to the tail vein of the rat (200 mg / kg) to induce endogenous hyperlipidemia. After 2 hours, blood was collected and hyperlipidemia-related indexes were measured by a biochemical analyzer (Automatic Analyzer, Hitachi 7020, Tokyo, Japan), and the results are shown in Table 2. The normal group was a group that did not cause hyperlipidemia, and the control group was a group treated with Triton and not treated in the same manner as the sample group. In the sample administration group, the inhibition rate of the biochemical index compared to the normal group was calculated as `` inhibition rate (%) = 100-(blood concentration at sample administration-blood concentration in normal group) / (control blood concentration-blood concentration in normal group) x 100 ''. It is shown by the method.

I. Experiment result

Test group Dose (mg / kg) Total Cholesterol (total chlolesterol) (mg / dl) Triglyceride (mg / dl) Triton RGAP   Summit Control - -    99.9 ± 10.0   156.3 ± 55.8   Control 200 - 132.9 ± 13.9 ^** 560.7 ± 82.2 ^**   RGAP 100 200 100   130.4 ± 27.6 517.5 ± 238.2 ^*   RGAP 200 200 200   132.2 ± 39.7 498.8 ± 163.7 ^**   RGAP 500 200 500   118.8 ± 24.3 464.7 ± 153.89 ^**   RGAP 1000 200 1000   112.8 ± 33.1 390.2 ± 128.79 ^{*, #} ** p <0.05, p <0.01 normal control vs control, # p <0.05 control vs administered group

As can be seen in Table 2, the result of administering RGAP 100mg / kg, 200mg / kg, 500mg / kg, 1000mg / kg to endogenous hyperlipidemia-induced rats shows that the total cholesterol content of the administration group is the content of Triton alone administration (control). This was increased by 1.3 times from 99.9 mg / dl to 132.9 mg / dl in the normal group, and 118.8 mg / dl and 112.8 mg / dl in the RGAP-administered 500 mg / kg and 1000 mg / kg groups, 42.7% and 60.9. % Showed a decrease in blood cholesterol concentration.

Triglyceride content was increased by 3.6 times from 156.3 mg / dl in the normal group to 560.7 mg / dl in the control group, but 517.5 mg / dl in the RGAP 100 mg / kg group was 10.7% compared to the normal control group and 498.8 mg / dl in the RGAP 200 mg / kg group. 15.1%, RGAP 500 mg / kg administration group was 464.7 mg / dl 23.7%, RGAP 1000 mg / kg administration group was 390.2 mg / dl 42.2% reduction effect was found to decrease depending on the concentration.

Therefore, RGAP can effectively improve hyperlipidemia caused by internal factors such as heredity in the family by reducing cholesterol and triglyceride levels for endogenous induced hyperlipidemia.

The present invention provides a dietary supplement containing red ginseng acid polysaccharide (RGAP) having antihyperlipidemic function in order to prevent the occurrence of disorders in the diet by acting as the greatest risk factor in hyperlipidemia.

In particular, the dietary supplement of the present invention selectively reduces only the concentration of triglycerides while maintaining the concentration of cholesterol to improve exogenous hyperlipidemia caused by the increase in the concentration of triglycerides due to the modern diet of increased fat intake, genetics, etc. Hyperlipidemia due to its internal factors may be useful for improving hyperlipidemia by containing red ginseng acid polysaccharides, which are functional food materials that reduce both cholesterol and triglyceride levels.

Claims (9)

As a health functional food containing red ginseng acid polysaccharide (RGAP) for improving endogenous hyperlipidemia, The red ginseng acid polysaccharide is extracted from red ginseng, glucuronic acid (glucuronic acid) 41.6 ~ 60.0 mol%, galacturonic acid (galacturonic acid) 2.5 ~ 7.5 mol%, glucose (glucose) 18.8 ~ 33.4 mol%, arabinose ( arabinose) 1.1 to 2.1 mol%, has a molecular weight of 12,000 to 450,000, Red ginseng acid polysaccharide-containing health functional food for improving endogenous hyperlipidemia, characterized in that the hyperlipidemia is hyperlipidemia induced by endogenous. delete The health functional food containing red ginseng acid polysaccharide for improving endogenous hyperlipidemia according to claim 1, wherein the health functional food is a solid food. The health functional food containing red ginseng acidic polysaccharide for improving endogenous hyperlipidemia according to claim 1, wherein the health functional food is a beverage or a polysaccharide. The health functional food according to claim 1, wherein the health functional food is selected from tablets, granules, capsules, and liquid formulations for improving endogenous hyperlipidemia. delete delete delete The health functional food containing red ginseng acid polysaccharide for improving endogenous hyperlipidemia according to claim 1, wherein the improvement of hyperlipidemia reduces the concentration of cholesterol and triglyceride.